Bi Yalan, Qu Yang, Liang Zhiyong, Liu Zichen, Zhang Hui, Liang Xiaolong, Luo Yufeng, Cao Jinling, Zhang Haiqing, Feng Ruie
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Pathol Res Pract. 2018 Apr;214(4):555-559. doi: 10.1016/j.prp.2018.02.006. Epub 2018 Feb 14.
The definition of large cell lung carcinoma (LCC) has undergone an extensive modification in the World Health Organization (WHO) Classification (2015). Present study aimed to investigate the clinicopathological characteristics of patients diagnosed as LCC according to current WHO criteria.
LCCs diagnosed based on the previous WHO classification were reevaluated, and 17 cases of LCC were finally identified at Peking Union Medical College Hospital and Beijing Chest Hospital between 2009 and 2015. The clinicopathologic features were examined and EGFR and KRAS mutations were tested. Survival of the patients was analyzed by Kaplan-Meier method.
The median age of the patients was 64 years (range: 40-78). Most patients were male (64.7%) and about half of the patients were at TNM stage III (47.1%). Morphologically, most cases (70.6%) were classic LCC. All patients were treated by lobectomy plus lymph node dissection, 2 with bi-lobectomy and 1 with complex lobectomy, and the other 2 patients were further treated by partial pericardiotomy. Ten patients received postoperative chemotherapy, while only 3 patients were treated with radiotherapy after surgery. Molecular analysis showed two cases of EGFR mutation (L858R) but without non-overlapping KRAS mutation. The 3-year overall survival rate was 48.4 ± 15.1%. Chemotherapy was the only predictive factor that is associated with the prognosis of the patients (P = 0.003).
The clinicopathological characteristics of 17 cases of stringently diagnosed LCC were retrospectively analyzed. LCC in our study showed aggressive behavior with high recurrence and metastasis and poor prognosis. Chemotherapy was only predictive factor that is significantly associated with the prognosis of the patients. Future studies based on a larger series and long term follow-up are still needed to characterize it further.
在世界卫生组织(WHO)分类(2015年)中,大细胞肺癌(LCC)的定义经历了广泛修订。本研究旨在调查根据当前WHO标准诊断为LCC的患者的临床病理特征。
对基于先前WHO分类诊断的LCC进行重新评估,2009年至2015年间在北京协和医院和北京胸科医院最终确定了17例LCC。检查临床病理特征并检测EGFR和KRAS突变。采用Kaplan-Meier法分析患者的生存率。
患者的中位年龄为64岁(范围:40 - 78岁)。大多数患者为男性(64.7%),约一半患者处于TNM III期(47.1%)。形态学上,大多数病例(70.6%)为经典LCC。所有患者均接受肺叶切除加淋巴结清扫术,2例行双肺叶切除术,1例行复杂肺叶切除术,另外2例患者进一步行部分心包切开术。10例患者接受了术后化疗,而只有3例患者术后接受了放疗。分子分析显示2例EGFR突变(L858R)但无重叠KRAS突变。3年总生存率为48.4±15.1%。化疗是与患者预后相关的唯一预测因素(P = 0.003)。
回顾性分析了17例严格诊断的LCC的临床病理特征。本研究中的LCC表现出侵袭性,复发和转移率高,预后差。化疗是与患者预后显著相关的唯一预测因素。仍需要基于更大样本系列和长期随访的未来研究来进一步明确其特征。